OP-94

Diabetes Mellitus, High Platelet Reactivity and Endothelial Dysfunction Determine the Outcomes after PCI. Elena Z. Golukhova, Marina V. Grigoryan, Maria N. Ryabinina, Naida I. Bulaeva. Department of

Noninvasive Cardiology, Bakoulev Scientific Center for Cardiovascular Surgery, Moscow, Russia.

Objective: The purpose of our study was to evaluate the prognostic value of platelet reactivity, initial level of inflammation markers and endothelial dysfunction, as well as CYP2C19*2 allele carriage in clinical outcomes after percutaneous coronary intervention (PCI) in patients with stable coronary artery disease (SCAD) during dual antiplatelet therapy (DAPT).

Methods: A prospective, single-center study included 94 patients with SCAD who underwent PCI with DES implantation. Platelet reactivity was determined in all patients using light transmission aggregometry induced with 5µmol/L ADP (LTA-ADP) and VerifyNow before PCI, as well as CYP2C19 genotyping after patient's discharge. In 74 patients were determined baseline levels of highsensitivity C-reactive protein, soluble P-selectin, soluble CD40 ligand, highly sensitive IL-6, PAI-1 levels and von Willebrand factor activity.

Results: According to univariate regression analysis we revealed that diabetes mellitus [exp (B) 0,344 95% CI 0,118-1,004, p=0,049], PRU [exp (B) 1,009; 95% CI 1,002-1,017, p=0.01], the number of stented arteries [exp (B) 4,00; 95% CI 1,475-10,848, p=0.01], the number of implanted stents [exp (B) 3,672; 95% CI 1,366-9,872, p=0.01], the initial level of PAI-1 [exp (B) 1,000, 95% CI 0,999-1,000, p=0.03] and the activity of EF [exp (B) 1,000, 95 1,000-1,000% CI, p=0.01]. The presence of CYP2C19*2 carriers showed no significant impact on outcomes after PCI. For quantitative factors we built ROC-curves to determine their critical values. Independent significant influence showed concomitant diabetes mellitus, PRU> =202, PAI-1 level> = 75.95 ng / ml, von Willebrand factor activity> = 155.15%. Based on our findings we developed predictive models for risk stratifying of patients with CAD before PCI.

Conclusions: The independent predictors of adverse cardiac events after PCI were: concomitant diabetes mellitus type 2, the value of PRU (≥202), the level of plasminogen activator inhibitor-1 (≥75.95 ng / ml) and von Willebrand factor activity(>155.15%).

OP-95

Assessment of Silent Cerebral Ischemia Following

Coronary Angiography Procedure. <u>Onur Sinan Deveci</u>¹, Firat Ikikardes¹, Aziz Inan Celik¹, Caglar Ozmen¹, Caglar Emre Cagliyan¹, Muhammet Bugra Karaaslan¹, Ali Deniz¹, Kenan Bıcakcı³, Sebnem Bıcakcı², Ahmet Evlice², Turgay Demir², Mehmet Kanadaşı¹, Mesut Demir¹, Mustafa Demirtas¹. ¹Cukurova University Faculty of Medicine Department of Cardiology; ²Cukurova University Faculty of Medicine Department of Neurology; ³Çukurova University Faculty of Medicine Department of Radiology.

Objective: Silent cerebral ischemia (SCI) is an embolic origin cerebrovascular lesion due to embolic vascular occlusion incidentally diagnosed. Coronary angiography (CAG) is established as the gold standard for the assessment of coronary artery disease. However there are minor and major complications related to the procedure. Retrospective data analysis revealed that 0.11% to 0.38% of patients undergoing CAG experienced clinically evident cerebral infarction whereas the incidence of SCI was 13% to 22%. To date, limited data were available regarding the occurrence and predictors of SCI after

Diagonis Cantar Asiografia						interation and		Baseline Characteristics				
1647 (Ta)	901() (pst54)	60e (28,5%)	15.25	lan? (Ka)	SCI(1) (ed. 32%)	903() (d6,6%)	-th/21		Total (m:101)	SCI(+) (a:12;12%)	SCI() (a:59; 55%)	pada Z. H
2:12	1713	11:182	1924	12:10	1:3	11:19	10.0	AEC	58 ± 11	65 = 10	11 ± 82	0.037
12.04	25	12.88	698.0	35	17	102	158.0	Sex Male / Female	59.42	0.6	50.39	0,350
15-18	21+12	12-1.85	482.0	3.5-845	15-885	位。後期	215.0	Carigo Asta Index. Ouracl	4.5 + 8.75	27 = 2.0	27,9" + 2,5	0.191
61230	1(5%)	42234	101	PERM	94034	9120X	278.0	Rypertmice	57 (56,4%)	7 (58,3 %)	50 (56,2 %)	0,999
UP408	10%	2 01%	(92.0	98 (B) R	44028	9120X	1560	Diaberes Mellitus	GP40.21-2 14	708340	37 (41,6%)	0,356
8182	(P10) E	P(38=	(91)	18196	(41)14	(P1801	1340	Hyperfigitencia	62 (61.4%)	7(58,3%)	55 (61,8 %)	0,999
22+22	2:14	(2+29	125.0	122+121	12+182	184482	1750	LDL	98 ± 45	105,7 = 38,1	97 ± 46	0,530
12-18	18-85	210-1100	458.0	1.8-40	22+80K	1日、日本市	810.0	Trials we wild a	239,5 + 56,3	0-3 × 8,00C	236,6 + 56,2	0,161
18:04	481+112	01+6273	121	(39-298)	10.000	15.915	4,514	Test Cholesteal	179.2 = 51.4	222.8 = 85.2	173.4 ± 79.6	840.0
15:16	II:tK	1211.6	121.1	52802	3.8 ± ± ± ± ± ±	622 = 22	985.0	LVEE	$57,9 \pm 8,9$	53.3 ± 9.2	58,5 ± 8,7	0.958
643D2	3 (75%)	\$112 S	188.0	1*(304	4410.5	67128-1	6.99	Smokers	59 (58.4%)	7 (58,3%)	52 (58,4%)	0,999
<u>E8+833</u>	赵延	25 #3	0.0	\$1+1M	\$1+2#E	(je18)	8000	Syntax Score	16,8±5,7	30,1 ± 2	15 ± 3	000,0
10,000	22+22	18+2	1723	18+5	141+23	41+35	256.0	Gensini Score	26.5 ± 35.6	58.8° = 55.66	22.1 ± 29.9	C.045
				97.80×	9134	P181	295.0	PCI / Diagnostic	2477	18	16.73	0,01
								Binesy of CABC	(475) 8	3 (25%)	(41,174) I	0,005
R:0	12=18	8:0	(20)	김리섬	1:12	산:13	1010	LDL: Low Density Lipuprotei	D. LVEF Lett	esticala Liection	Fraction.	
4 Mi inté	C. stal table (s)	L In Daipter	N BOL inte	i Veticie Beti	SEA ninels	end cash yana)	anital a	Simt Cerebral Ischemia	ACS Jacobserverage	or gaunned on	reach searching Tax	The June
		Approximation Approximation Approximation Approximation <t< td=""><td>Biologic Amarging (Second Second Se</td><td>Bayes Construction Construction 20 67.0 67.0 67.0 20 67.0 67.0 67.0 20 67.0 67.0 67.0 20 67.0 67.0 67.0 20 67.0 67.0 67.0 20 20.0 70.0 67.0 20 20.0 20.0 20.0 20 20.0 20.0 20.0 20 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0</td><td></td><td>Operation Operation <t< td=""><td></td><td>$\begin{array}{ c c c c c c c c c c c c c c c c c c c$</td><td>$\begin{array}{ c c c c c c c c c c c c c c c c c c c$</td><td>$\begin{array}{ c c c c c c c c c c c c c c c c c c c$</td><td>$\begin{array}{c c c c c c c c c c c c c c c c c c c$</td><td>$\begin{array}{ c c c c c c c c c c c c c c c c c c c$</td></t<></td></t<>	Biologic Amarging (Second Second Se	Bayes Construction Construction 20 67.0 67.0 67.0 20 67.0 67.0 67.0 20 67.0 67.0 67.0 20 67.0 67.0 67.0 20 67.0 67.0 67.0 20 20.0 70.0 67.0 20 20.0 20.0 20.0 20 20.0 20.0 20.0 20 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0 20.0		Operation <t< td=""><td></td><td>$\begin{array}{ c c c c c c c c c c c c c c c c c c c$</td><td>$\begin{array}{ c c c c c c c c c c c c c c c c c c c$</td><td>$\begin{array}{ c c c c c c c c c c c c c c c c c c c$</td><td>$\begin{array}{c c c c c c c c c c c c c c c c c c c$</td><td>$\begin{array}{ c c c c c c c c c c c c c c c c c c c$</td></t<>		$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$

Table.

CAG. In our study we aim to evaluate the incidence and predictors of SCI after CAG.

Method: One hundred one stable coronary artery disease patients without atrial fibrillation and history of serebrovascular disorders underwent coronary anjiography and intervention were included in this study. Percutaneous coronary interventions were performed for selected patients. Cerebral magnetic resonance imaging and diffusion weighted magnetic resonance imaging (DW-MRI) were performed within 24 hours after diagnostic coronary anjiography. Silent cerebral infarction (SCI) was diagnosed with the presence of focal bright high signal intensity on DW-MRI. Patients were divided into diagnostic coronary anjiography and intervention group. Each groups were assessed with presence or absence of SCI. The laboratory findings, clinical and angiographic characteristics were analyzed and compared between patients with and without SCI on DW-MRI.

Results: Total of 101 included patients, SCI occured 24 (24 %) patients. Sex, body mass index, hypertension, diabetes mellitus, LDL, triglyceride, smoking, left ventricular ejection fraction (LVEF) were not significant between SCI (+) and SCI (-) groups. Age, total cholesterol, syntax score, gensini score, CABG history were significantly higher in SCI (+) group compared with SCI (-) group with statistical datas (table-1) respectively (65 \pm 10 vs 58 \pm 11, p: 0,037; 222.8 \pm 85.2 vs 173.4 \pm 79.6, p: 0.048; 30,1 \pm 2 vs 15 \pm 3, p: 0,000; 58,8 \pm 55,6 vs 22,1 \pm 29,9, p: 0,045; 3 (25%) vs 1 (1,1%), p: 0,005) SCI were observed significantly higher in intervention group. (8/24 vs 4/77, p:0,01). Subgroup analyses for diagnostic coronary angiography and intervention groups were performed (table-2). Syntax score was significantly higher in SCI (+) patients in each groups respectively. (29.3 \pm 1.9 vs 15 \pm 3, p<0.01; 30.5 ± 1.9 vs 15.1 ± 3.2 , p<0.01)

Conclusion: The incidence of SCI after diagnostic and interventional CAG was not infrequent. Higher age, total cholesterol, syntax score, gensini score and CABG evaluation are associated with SCI.

OP-96

The Phenomenon of Periprocedural High on-Treatment Platelet Reactivity During PCI: Clinical, Genetic and Inflammation Determinants. Elena Z. Golukhova, Marina V. Grigoryan, Maria N. Ryabinina, Naida I. Bulaeva. Deparment of Noninvasive Cardiology, Bakoulev Scientific Center for Cardiovascular Surgery, Moscow, Russia.

Objective: We aimed to determine different laboratory and genetic factors impact on high on-treatment platelet reactivity (HOPR) on dual antiplatelet therapy (DAPT).

Methods: Our study included 94 patients with SCAD (mean age 59 \pm 9,67 years). All patients underwent elective PCI with DES implantation during dual antiplatelet therapy (aspirin and clopidogrel). Platelet function was assessed by light transmission aggregometry with 5µmol/

542 The American Journal of Cardiology® MARCH 26–29, 2015 11th INTERNATIONAL CONGRESS OF UPDATE IN CARDIOLOGY AND CARDIOVASCULAR SURGERY ABSTRACTS / Oral